| Nov 18 |
GRCE: FY:25 Second Quarter Results
|
| Nov 15 |
Grace Therapeutics And 2 Other US Penny Stocks To Watch
|
| Nov 13 |
Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06
|
| Nov 13 |
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
|
| Nov 4 |
GRCE: Initiating Coverage – From Confusion to Infusion
|
| Oct 29 |
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR
|
| Oct 25 |
Acasti Pharma changes name to Grace Therapeutics
|
| Oct 25 |
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
|
| Sep 25 |
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
|
| Sep 20 |
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
